The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
about
PD-1/PD-L1 blockades in non-small-cell lung cancer therapyPredictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysisThe anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsPrognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis.PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer TreatmentClinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung CancerProgrammed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor.The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)Association of tumor TROP2 expression with prognosis varies among lung cancer subtypesImmune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung CancerExpression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survivalUpregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patientsPD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutationsProgrammed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma.Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC.PD-L1 Expression in Lung Cancer.Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress.Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.Lung Cancer Staging and Prognosis.Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.Resistance to Therapy.The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells.Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response.KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma.PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.PD-L1 and c-MET expression and survival in patients with small cell lung cancer.PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
P2860
Q26765024-4CD55E58-BB09-4678-A8AC-16A69B2E8707Q26769728-7BB23E76-D8C1-4EAA-8698-49F0EBC028AAQ26797478-42684AAE-DF69-4C30-9E87-E68444650E4EQ27853291-C719651D-CE1C-4856-B4A9-751F34D39C0AQ27853353-ECB91DF3-6C90-43CB-95A7-01CE75BE2AA4Q28069424-71FB6D80-AB90-4AB0-9831-55021FCA9372Q28084766-352C78C1-702D-4BA3-A636-AEDAD0B2A0C2Q33607407-C26E7D2F-0DEB-492E-A80D-F5BA5B057360Q33618747-3B7436E5-88FC-4134-A6F0-5B6B95FB8D05Q33644049-85DD21EB-00DA-4C60-81CF-FF295E2BDA54Q33688849-1976B647-6AD2-4024-B86D-D3276713029EQ33709864-C255E752-5CD7-4E74-A417-326A9D226336Q36088496-B12CE8C9-B8DE-4D5C-B236-19F07D7F52A0Q36517199-F6907AEF-2559-49F8-B340-E3C75D6A38F0Q36545054-5F7A46B4-C29A-4D5E-849D-BDD03A7EA317Q36821248-BCC83F3E-9376-4E53-BC0E-2A9719BB8BE7Q37013280-0BE09656-854F-4673-BE71-419552338575Q37094056-5F544BB3-2DED-4E80-BDC7-1F19F38F3C9EQ37362623-D5DAE81A-E628-44B1-89ED-FE122E1B1A96Q37564425-D8DF1276-D835-4C4E-8072-F40836E8256FQ37650062-146E997E-0183-4E96-B2A8-63F72190A235Q37675926-92DE07D2-E206-4AFE-A7FC-5B1573B2BC90Q37704352-5A0AE785-CB38-42F9-8140-530E904920F2Q38646686-ADC5A8F7-B52F-4216-95EF-9AE749102C80Q38720801-38AC396B-925E-47E6-BAF1-FC2ABB5719ABQ38746756-7110CA71-F650-4C8B-991C-72F798240080Q38830349-8652E562-B6D1-42C7-AD60-AAAFE0882AD4Q38902971-34736D0C-1F0F-471E-88CD-2292297F7A0BQ38930367-E62B9A93-D272-4FF2-9F8A-1440DCA00D07Q38998427-4648D602-1AD0-477F-BF5E-6E557C38DE53Q39194722-AA7D567F-D250-4564-B7DB-7421266606DAQ40223999-345BDC52-6B8C-464C-B372-65C60E9ED01AQ40610329-BF0AF875-112C-417C-9F0C-52B0BE270CE4Q40626934-0CC4E986-61CC-4595-8A64-B8384B6E6A90Q40745198-BA1F826E-1B54-4859-80EF-23415A0C0EF1Q41112103-DD64E01E-974E-4DB5-A1E9-EB2E079C525BQ41306256-FDAB727A-91FF-468A-A726-4A77299BE651Q41553643-1DAC1603-A1FE-4B54-A493-DF7DB49C7783Q41579669-2D4CA058-3DC2-4E13-B89C-1E342A27CB4CQ41912025-33C72B50-6F8C-45C1-93B5-5668A2BE3F5D
P2860
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The association between PD-L1 ...... atients treated with EGFR-TKIs
@ast
The association between PD-L1 ...... atients treated with EGFR-TKIs
@en
type
label
The association between PD-L1 ...... atients treated with EGFR-TKIs
@ast
The association between PD-L1 ...... atients treated with EGFR-TKIs
@en
prefLabel
The association between PD-L1 ...... atients treated with EGFR-TKIs
@ast
The association between PD-L1 ...... atients treated with EGFR-TKIs
@en
P2093
P2860
P356
P1433
P1476
The association between PD-L1 ...... atients treated with EGFR-TKIs
@en
P2093
Jianhua Zhan
Peijian Peng
Shaodong Hong
Shiyang Kang
Wenfeng Fang
Wenyi Tang
P2860
P304
14209-14219
P356
10.18632/ONCOTARGET.3694
P407
P577
2015-06-01T00:00:00Z